Abstract: The present invention relates to ophthalmic compositions for the treatment of ocular hypertension and glaucoma, comprising a hypotonic solution of 0.1 to 0.2% (w/w) of xanthan gum and 0.5 to 5% (w/w) of a topical carbonic anhydrase inhibitor or an ophthalmologically acceptable salt thereof.

Abstract: There is described a fluid ophthalmic composition which comprises a suspension in a fluid dispersant medium of lipid microparticles containing at least one active principle. The composition enables improved availability of the active principle to be obtained as a result of high intraocular levels.

Abstract: The present invention concerns a fluid pharmaceutical composition intended to be brought into contact with a physiological fluid, characterized in that it contains, as active principle, at least one 4-quinolone derivative complexed with a divalent metal ion selected from Cu.sup.++, Zn.sup.++ and Mg.sup.++, the said complex being in the form of particles of a size compatible with parenteral or ophthalmic administration, in suspension in a fluid dispersant and not being subject to a crystalline growth phenomenon during storage of the said composition; the invention also provides a process for preparing a pharmaceutical composition of this type.